Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI) -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (269)	5/3/1999 4:41:00 PM
From: Steven Rachbach	Read Replies (1) \| Respond to of 1127

David, You write, "So, this stock probably won't move until some time next century." Clinical trials require a lot of planning, extensive testing and careful analysis in order to ultimately provide patients with the most efficacious and safest medications available. Based on the initiation dates of Phase II testing of MPIF-1, KEGF-2 and VEGF-2, results will probably begin to be reported early next year. For the rest of this year/century, you will have to be content with general market influences, sector news, and positive/negative anticipation of the results of the trials to "move" the stock price. Beginning next year/century/millenium, the Phase II results will be crucial. I have nothin' but time... Regards, Steve Rachbach